Outcome Prediction of Treatment of Graves' Hyperthyroidism with Antithyroid Drugs.
Study Goal
The researchers aimed to evaluate the role of iodine in Graves' disease treatment and the factors influencing relapse after antithyroid drug therapy.
Results Summary
The study highlights that antithyroid drugs (ATDs) are first-line treatment in Europe but have high relapse rates, particularly in patients with large thyroid volume, smoking habits, persistent TRAb, or post-partum status. Definitive therapies like radioiodine or thyroidectomy are recommended for high-risk patients.
Population
Patients with Graves' disease in iodine-replete areas.
Effective Dosage
Not specified
Duration
18-24 months (ATD treatment duration)
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Antithyroid drugs (ATDs) belonging to the family of thionamides | no change | Graves' disease | patients in Europe | - | first-line treatment | #1 |
ATD treatment | no change | treatment duration | - | 18-24 months | commonly continued for | #2 |
ATD treatment | increase | relapse rate | - | high | high rate of relapses after drug withdrawal | #3 |
large thyroid volume | increase | relapse risk | - | - | bound to subsequent relapses | #4 |
smoking habit | increase | relapse risk | - | - | bound to subsequent relapses | #5 |
persistence of TRAb in the circulation at the end of treatment | increase | relapse risk | - | - | bound to subsequent relapses | #6 |
post-partum period | increase | relapse risk | - | - | bound to subsequent relapses | #7 |
persistence or recurrence of hyperthyroidism | increase | cardiovascular complications | patients at risk of cardiovascular complications | - | might be exacerbated | #8 |
Graves' disease is the most common cause of hyperthyroidism in iodine-replete areas and is ultimately due to antibodies interacting with the TSH receptor on thyroid follicular cells [TSH-receptor antibody (TRAb)]. Antithyroid drugs (ATDs) belonging to the family of thionamides are the first-line treatment in Europe. ATD treatment is commonly continued for 18-24 months. Its major limitation is the high rate of relapses after drug withdrawal. Factors particularly bound to subsequent relapses are the large thyroid volume, smoking habit, persistence of TRAb in the circulation at the end of treatment, and the post-partum period. Under these conditions, consideration should be given to a definitive therapy for hyperthyroidism (radioiodine treatment, thyroidectomy), particularly if the patient is at risk of cardiovascular complications that might be exacerbated by persistence or recurrence of hyperthyroidism.